Keyword: Giovanni Caforio
Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.
On Dec. 10, Bristol-Myers Squibb made what it said was its final offer to buy Celgene. But it ended up striking a better deal instead.
Ever wish you could be a fly on the wall at a company in the middle of a merger? Thanks to the Securities and Exchange Commission, you can.
BMS execs faced a tough audience during its Q4 report, as analysts pressed them for details about how the Celgene merger would drive growth.
Pharma came storming out of the gate at this year's J.P. Morgan meeting in a Monday full of deal talk, CEO ambitions and analyst prognostications.
On Bristol-Myers Squibb’s Thursday third-quarter conference call, executives plunged right into investors' doubts.
You could almost say that Bristol-Myers Squibb’s story is all about immuno-oncology, what with the high-profile cancer-fighter Opdivo grabbing most of its 2017 headlines. But a come-from-behind anticoagulant, Eliquis, is pulling almost-equal weight these days, and together they pushed the company to a 7% revenue rise in 2017.
Following a big finish in the fourth quarter, Bristol-Myers' CEO took home a 10% pay raise for 2017 to $18.7 million.
There's "still significant growth ahead” for next-gen anticoagulant Eliquis, the way Bristol-Myers Squibb CEO Giovanni Caforio sees it.
Last year, Opdivo racked up billions in sales and a range of new indications, and that helped boost Bristol-Myers Squibb CEO Giovanni Caforio's salary base by 17%.